Download PDF
Semin intervent Radiol 2024; 41(01): 011-015
DOI: 10.1055/s-0043-1778658
Review Article

Intra-arterial Peptide Receptor Radionuclide Therapy for the Treatment of Hepatic Neuroendocrine Tumor Metastases: Hope or Hype?

Michael V. Khanjyan
1   Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
,
Nicholas Fidelman
1   Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Peptide receptor radionuclide therapy (PRRT) confers significant progression-free survival advantage for patients with small bowel grade 1 and 2 well-differentiated neuroendocrine tumors (WD NET). PRRT may also be clinically beneficial for patients with NET of pancreatic, bronchial, and other sites of origin; patients with paragangliomas; as well as for patients with well-differentiated grade 3 NET. Direct intra-arterial (IA) administration of PRRT into the hepatic artery for patients with NET liver metastases may result in higher radiopharmaceutical dose and longer dwell time in the liver tumors while relatively sparing non-tumor liver tissue and other organs such as the kidneys and bone marrow when compared with intravenous (IV) administration. This review summarizes currently available data on IA and IV PRRT dose distribution, reports safety and efficacy of IA PRRT, and proposes future research questions.

Keywords

interventional radiology - liver cancer - neuroendocrine - peptide receptor radionuclide therapy


Publication History

Article published online:
14 March 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Fairweather M, Swanson R, Wang J. et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol 2017; 24 (08) 2319-2325
    CrossrefPubMedGoogle Scholar
  • 2 Strosberg JR, Caplin ME, Kunz PL. et al; NETTER-1 Investigators. 177Lu-DOTATATE plus long-acting octreotide versus high–dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22 (12) 1752-1763
    CrossrefPubMedGoogle Scholar
  • 3 Caplin ME, Pavel M, Ćwikła JB. et al; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371 (03) 224-233
    CrossrefPubMedGoogle Scholar
  • 4 Bergsma H, van Vliet EI, Teunissen JJM. et al. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol 2012; 26 (06) 867-881
    CrossrefPubMedGoogle Scholar
  • 5 Strosberg J, El-Haddad G, Wolin E. et al; NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedGoogle Scholar
  • 6 Bodei L, Kidd M, Paganelli G. et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015; 42 (01) 5-19
    CrossrefPubMedGoogle Scholar
  • 7 Kratochwil C, Giesel FL, López-Benítez R. et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2010; 16 (10) 2899-2905
    CrossrefPubMedGoogle Scholar
  • 8 Kratochwil C, López-Benítez R, Mier W. et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer 2011; 18 (05) 595-602
    CrossrefPubMedGoogle Scholar
  • 9 Limouris GS, Poulantzas V, Trompoukis N. et al. Comparison of 111In-[DTPA0]octreotide versus non carrier added 177Lu- [DOTA0, Tyr3]-octreotate efficacy in patients with GEP-NET treated intra-arterially for liver metastases. Clin Nucl Med 2016; 41 (03) 194-200
    CrossrefPubMedGoogle Scholar
  • 10 Thakral P, Sen I, Das SS, Manda D, Cb V, Malik D. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. Br J Radiol 2021; 94 (1126): 20210403
    CrossrefPubMedGoogle Scholar
  • 11 Lawhn-Heath C, Fidelman N, Chee B. et al. Intraarterial peptide receptor radionuclide therapy using 90Y-DOTATOC for hepatic metastases of neuroendocrine tumors. J Nucl Med 2021; 62 (02) 221-227
    CrossrefPubMedGoogle Scholar
  • 12 Cremonesi M, Ferrari ME, Bodei L. et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging 2018; 45 (13) 2426-2441
    CrossrefPubMedGoogle Scholar
  • 13 Limouris GS, Karfis I, Chatzioannou A. et al. Super-selective hepatic arterial infusions as established technique (‘ARETAIEION’ Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors. Q J Nucl Med Mol Imaging 2012; 56 (06) 551-558
    PubMedGoogle Scholar
  • 14 Kolasińska-Ćwikła A, Nowicki ML, Sankowski AJ. et al. Radiological and clinical efficacy of intra-arterial 90Y-DOTATATE in patients with unresectable, progressive, liver dominant neuroendocrine neoplasms. J Clin Med 2021; 10 (08) 1794-1809
    CrossrefPubMedGoogle Scholar
  • 15 Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials 2020; 21 (01) 141-149
    CrossrefPubMedGoogle Scholar